Latest Breaking News On - Permanent product measure - Page 1 : vimarsana.com

FDA Clears Cingulate to File NDA for CTx-1301 in the Treatment of ADHD

The company has announced plans to submit the NDA in the first half of 2025.

Cingulate Shares Fall to 52-Week Low After Reverse Split

By Josh Beckerman Shares of Cingulate, which is developing drugs using its Precision Timed Release technology, fell to a 52-week low after a 1-for-20 reverse.

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Inc (CING) Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301

Cingulate Sees Positive Results in Trial for ADHD Treatment

By Chris Wack Cingulate said it saw positive results from a Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301, for the treatment of.

ADHD-Focused Cingulate Prices Public Offering, Shares Detailed Pivotal Trial Data - Cingulate (NASDAQ:CING)

Cingulate Inc (NASDAQ: CING) shares are trading lower after the company priced its $4-million public offering at around 58 cents per share 

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and DurationKANSAS CITY, Kan., July 11, 2023 Cingulate Inc. , a biopharmaceutical company utilizing its.

Cingulate Inc (CING) Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 for ADHD

Why Are Cingulate Shares Trading Higher Today? - Cingulate (NASDAQ:CING)

Cingulate Inc (NASDAQ: CING) announced topline results from its Phase 3 adult trial of its lead candidate, CTx-1301 (dexmethylphenidate) for attention-deficit/

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD